Cuban vaccines vs big Pharma

https://today.in-24.com/News/10581.html

Cuban vaccines showing progress :

Abdala 92% eficacy with 3 doses!

Soberana02 62% with 3 doses (possibly soon will prove >80-90%) with 3 doses..

Pending 

Soberana02 in children  (possibly the best suited for chil immunization programmes as they are linked to tetanus, HBV and Hib)

Soberana+ single dose for  pre-infected and  convalescebts

Mambisa vía intranasal for other contexts

All with traditional processes and low resources, open to technology transfer and aimed at global health equity despite extreme economic hardship maily due to tough blockade by Trump, maintained by Biden..

Private vaccines by big Pharma	Cuban vaccines
investment	Average 2 Bn per vaccine	No additional financing
CEO salary	Over one million US$/m	Less than 1000 US$/m
Distribution beyond national	Bilateral contracts with rich countries	Aim to support low income countries
method	mRNA (novel mechanism with unknown mid-long term effects)	Viral protein with carrier
results	>90% after two doses in non-new variants context	>90% after three doses (Abdala) in new variants context
Media coverage	All global media coverage	Silenced in most global media
Patent policy	Protecting patent monopoly	Open to technology transfer and vaccine global equity
concept	Merchandise aimed at shareholders’ profits	Global Public Good aimed at global health equity and universal right to health